Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3775-3782

  Kaira, Kyoichi ^a   Takahashi, Toshiaki ^a   Murakami, Haruyasu ^a   Shukuya, Takehito ^a   Kenmotsu, Hirotsugu ^a   Naito, Tateaki ^a   Oriuchi, Noboru ^b   Kanai, Yoshikatsu ^c   Endo, Masahiro ^a   Kondo, Haruhiko ^a   Nakajima, Takashi ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Advanced NSCLC; CD98; Chemotherapy; EGFR mutation; Ki 67; LAT1; p Akt; p mTOR; Prognosis; Recurrence

Indexed keywords

AMRUBICIN; CARBOPLATIN; CARRIER PROTEIN; CD98 ANTIGEN; CISPLATIN; DOCETAXEL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; KI 67 ANTIGEN; L TYPE AMINO ACID TRANSPORTER 1; MAMMALIAN TARGET OF RAPAMYCIN; NAVELBINE; PACLITAXEL; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANTIGENS, CD98; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83055191349     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Oxender DL and Christensen HN: Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature 197: 765-767, 1963.
2. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E and Endou H: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273: 23629-23632, 1998. (Pubitemid 28435687)
3. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T and Endou H: Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514: 291-302, 2001. (Pubitemid 32831016)
4. Fuchs BC and Bode BP: Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semi Cancer Biol 15: 254-266, 2006.
5. Yamauchi K, Sakurai H, Kimura T, Wiriyasermkul P, Nagamori S, Kanai Y, Kohno N: System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Lett 276: 95-101, 2009.
6. Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Nagamori S, Promchan K, Nakajima T, Yamamoto N, Mori M and Kanai Y: Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res 30: 4819-4828, 2010.
7. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M: Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98: 742-748, 2008. (Pubitemid 351272621)
8. La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, Fumarola C, Bonelli M, Generali D and Petronini PG: Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochemical Pharm 78: 460-468, 2009.
9. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F and Tortora G: Inhibition of mTOR pathway by everplimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR. Br J Cancer 98: 923-930, 2008. (Pubitemid 351341618)
10. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, Saito R, Maruyama Y, Kawahara M and Ignatius Ou SH: Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer. A comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 5: 620-630, 2010.
11. Kaira K and Yamamoto N: Prognostic and predictive factors in resected non-small cell lung cancer. Expert Opin Med Diagn 4: 373-381, 2010.
12. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Nakajima T and Mori M: Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 66: 120-126, 2009.
13. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M: Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci 100: 249-254, 2009.
14. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T and Mori M: CD98 expression is associated with poor prognosis in resected non-small cell lung cancer with lymph node metastasis. Ann Surg Oncol 16: 3473-3481, 2009.
15. Imai H, Kaira K, Oriuchi N, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M: L-Type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Histopathology 54: 804-813, 2009.
16. Mountain CF: Revision in the International System for Staging Lung Cancer. Chest 11: 1710-1717, 1997.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
18. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y and Endou H: L-Type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119: 484-492, 2006. (Pubitemid 43955699)
19. Chairoungdua A, Segawa H, Kim JY, Miyamoto K, Haga H, Fukui Y, Mizoguchi K, Ito H, Takeda E, Endou H, Kanai Y: Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J Biol Chem 274: 28845-28848, 1999.
20. 18F]-fluoro-2-deoxy-D-glucose uptake on positron-emission tomography in thymic epithelial tumors. J Clin Oncol 28: 3746-3753, 2010.
21. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K and Kanazawa M and Hagiwara K: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282, 2005. (Pubitemid 41161259)
22. Uchino H, KanaiY, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW and Endou H: Transport of amino acid-related compounds mediated by L-Type amino acid transporter 1 (LAT1): Insights into the mechanisms of substrate recognition. Mol.Pharmacol 61: 729-737, 2002. (Pubitemid 34273151)
23. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med 50: 1770-1776, 2009.
24. Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Oyama T, Mori M and Endo K: Comparison of LAT1 expression and 18F-FAMT uptake in outcome of non-small cell lung cancer. Nucl Med Biol 37: 911-916, 2010.
25. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K and Fukuoka M: Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung harbouring mutations of the epidermal growth factor receptor (WJTOG 3405): an open label, randomized phase 3 trial. Lancet Oncol 11: 121-128, 2010.
26. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S and Nukiwa T: Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 36: 2380-2388, 2010.
27. Shennan DB and Thomson J: Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncol Rep 20: 885-889, 2008.
28. Fan X, Ross DD, Arakawa H, Ganapathy V, Tamai I and Nakanishi T: Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. Biochemical Pharm 80: 811-888, 2010.
29. Kanai Y and Endou H: Heterodimetric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab 2: 339-254, 2001.
30. Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y and Tamura T: Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol 4: 518-521, 2009.